The Business Times
The Business Times
Subscribe
Share on FacebookShare on TwitterView more
The Business Times
Create a free account with Business Times for seamless access across SPH Media products.
REGISTER
LOGIN

Companies & Markets

SUBSCRIBERS

Allergan bets on rising popularity of botox for men

Move is part of firm's strategy to go after smaller markets in traditional pharmaceutical industry

Published Thu, Jun 18, 2015 · 09:50 PM
Share this article.

New York

FINE lines. Double chins. Sagging skin. Allergan Plc is betting that these byproducts of ageing are becoming an obsession for men.

After completing a deal valued at US$70.5 billion to buy the maker of Botox injections, Allergan announced on Wednesday that it would pay US$2.1 billion for Kythera Biopharmaceuticals Inc. The latest transaction gives the company an experimental drug for male-pattern baldness and an injection that is the only regulator-approved non-surgical treatment for a double chin - a condition that Kythera has said bothers men as much as women.

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to  t.me/BizTimes

Consumer & Healthcare

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

Get the latest coverage and full access to all BT premium content.

SUBSCRIBE NOW

Browse corporate subscription here